Who are A-101 Solution 40's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SOLIFENACIN SUCCINATE, DICYCLOMINE, Aceclidin, Xanomeline and Trospium Chloride, Tolterodine Tartrate ER, Tolterodine 6.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/a-101-solution-40.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

A-101 Solution 40 — Competitive Intelligence Brief

A-101 Solution 40 (A-101 Solution 40) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: anticholinergic. Area: Dermatology.

phase 2 anticholinergic muscarinic receptors Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

A-101 Solution 40 (A-101 Solution 40) — Aclaris Therapeutics, Inc.. A-101 Solution 40 is a topical solution used to treat hyperhidrosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
A-101 Solution 40 TARGET	A-101 Solution 40	Aclaris Therapeutics, Inc.	phase 2	anticholinergic	muscarinic receptors
SOLIFENACIN SUCCINATE	SOLIFENACIN SUCCINATE		marketed		Muscarinic receptors	2004-01-01
DICYCLOMINE	DICYCLOMINE		marketed	Antispasmodic and anticholinergic (antimuscarinic) agent	Muscarinic receptors	1950-01-01
Aceclidin	ACECLIDINE		marketed	aceclidine	muscarinic receptors
Xanomeline and Trospium Chloride	Xanomeline and Trospium Chloride	Collaborative Neuroscience Research, LLC	marketed	Muscarinic M1/M4 receptor agonist with peripheral anticholinergic antagonist	Muscarinic acetylcholine receptors M1 and M4 (xanomeline); muscarinic receptors peripherally (trospium chloride antagonism)
Tolterodine Tartrate ER	Tolterodine Tartrate ER	University of California, San Francisco	marketed	Muscarinic receptor antagonist	M2 and M3 muscarinic receptors
Tolterodine 6	Tolterodine 6	KYU-SUNG LEE	marketed	Muscarinic receptor antagonist	M2 and M3 muscarinic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (anticholinergic class)

Aclaris Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). A-101 Solution 40 — Competitive Intelligence Brief. https://druglandscape.com/ci/a-101-solution-40. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab